RNase-PON1 Fusion Polypeptides for Quorum Sensing and NET Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for lung diseases such as COPD and asthma are inadequate, and there is a need for new targets and approaches to address lung inflammation and infections caused by P. aeruginosa, particularly in conditions like cystic fibrosis, where oxidative stress and extracellular DNA contribute to tissue damage and biofilm formation.
Innovation Solution
Development of RNase-PON1 fusion polypeptides that combine the enzymatic activities of paraoxonase 1 (PON1) and ribonuclease (RNase) to target and degrade quorum sensing molecules and extracellular DNA, thereby reducing lung inflammation and biofilm formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies (nebulized steroids, anticholinergics, bronchodilators) are used for lung diseases, then existing treatment protocols are maintained, but therapeutic efficacy is insufficient for severe cases and new disease targets are not addressed
Solution Approach 1:
The patent combines DNase1 and PON1 into a single fusion protein molecule, allowing simultaneous delivery of both enzymatic activities to the lung tissue. This merging approach addresses the limitation of current monotherapy by providing dual mechanism action (DNA degradation and oxidative stress reduction) through a single administered agent, thereby improving therapeutic efficacy while maintaining treatment simplicity
Solution Approach 2:
The fusion protein serves multiple therapeutic functions: DNase1 activity degrades extracellular DNA and NETs to reduce inflammation, while PON1 activity provides antioxidant protection and anti-inflammatory effects. This multi-functionality allows a single agent to address multiple pathogenic mechanisms in lung diseases, enhancing both efficacy and adaptability across different disease severities
2Object-affected harmful factors
If DNase1 is administered alone to digest NETs and reduce mucus viscosity, then lung clearance is improved, but oxidative stress and inflammation are not adequately addressed
Solution Approach 1:
The fusion protein combines DNase1 and PON1 into a single molecular entity that can simultaneously address both extracellular DNA degradation and oxidative stress reduction. The DNase1 portion degrades NETs and extracellular DNA to improve lung clearance, while the PON1 portion provides antioxidant protection against oxidative stress, thereby addressing both harmful factors mentioned in the contradiction
Solution Approach 2:
The fusion protein acts as an intermediary that bridges two therapeutic mechanisms: the DNase1 component handles DNA degradation while the PON1 component handles oxidative stress. This intermediary approach allows coordinated action between the two enzymatic activities, ensuring that both harmful factors (extracellular DNA and oxidative stress) are addressed simultaneously through a single therapeutic agent
3Object-generated harmful factors
If PON1 is used alone to provide antioxidant protection, then oxidative stress is reduced, but extracellular DNA and NETs are not degraded
Solution Approach 1:
The fusion protein merges PON1 antioxidant protection with DNase1 DNA degradation capabilities into a single therapeutic agent. While PON1 provides the antioxidant protection against oxidative stress, the integrated DNase1 component simultaneously degrades extracellular DNA and NETs, ensuring that both harmful factors are addressed by the same administered protein
4Object-affected harmful factors
If separate administrations of DNase1 and PON1 are used, then both DNA degradation and antioxidant protection are provided, but treatment complexity and dosing burden increase
Solution Approach 1:
The fusion protein consolidates two separate therapeutic agents (DNase1 and PON1) into a single molecular entity. This merging eliminates the need for separate administrations, simplified dosing schedules, and multiple injection sites, thereby reducing treatment regimen complexity while maintaining the dual therapeutic benefits of DNA degradation and antioxidant protection
Solution Approach 2:
The fusion protein serves as a universal therapeutic agent that performs both DNase1 and PON1 functions through a single administration. This multi-functionality approach allows one protein to replace two separate treatments, reducing the burden on patients and simplifying clinical protocols while addressing multiple pathogenic mechanisms simultaneously
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNase-PON1 fusion polypeptides effectively inhibit P. aeruginosa quorum sensing and degrade neutrophil extracellular traps (NETs), providing a dual mechanism to reduce lung inflammation and enhance therapeutic outcomes in lung diseases.
Implementation Method 1
DNase1 can digest NETS and reduce the viscosity of mucus, allowing improved lung clearance
Implementation Method 2
PON1 has multiple substrates, including organophosphates and acyl homoserine lactones, the quorum sensing molecules made by Pseudomonas aeruginosa
Data Source
AI summary
Compositions and methods relating to paraoxonase fusion polypeptides are disclosed. In some aspects, the fusions are bispecific molecules that include a first biologically active polypeptide linked amino-terminal to a biologically active paraoxonase, wherein the first biologically active polypeptide is a DNase, an RNase, a SOD1, a CTLA-4 extracellular domain, a CD40 extracellular domain, or a polypeptide that specifically binds and neutralizes an inflammatory cytokine. Bispecific fusions may further include a second biologically active polypeptide (e.g., a dimerizing or FcRn-binding domain) linked carboxyl-terminal to the first biologically active polypeptide and amino-terminal to the paraoxonase. In other aspects, a fusion polypeptide includes a biologically active paraoxonase linked carboxyl-terminal or amino-terminal to a dimerizing or FcRn-binding domain. Also disclosed are dimeric proteins comprising first and second paraoxonase fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.